Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0030567 (Parkinson's disease)
 63,064 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

W. Kostowski's The Pathomechanism and Pharmacotherapy of Parkinson's Disease was published in 1987. M. Weissel's Thyroid Gland Hormones Can Affect the Plasma Level of Atrial Urinary Sodium Peptide in Man was issued in Die Schilddruse in 1987. The following articles were published in the New England Journal of Medicine: 1. Madrazo's Microsurgical Graft of Adrenal Medulla to the Right Caudate Nucleus in Two Patients with Intractable Parkinson's Disease in 1987. R. Noore's Parkinson's Disease--A New Therapy? in 1987. F. Needelman's A Cardiac Hormone Intimately Involved in Fluid, Electrolyte, and Blood Pressure Homeostasis in 1986. G. Dersy's Arterial Endocrine Function in Humans with Artificial Hearts in 1987. W. Crowley's Progesterone Antagonism in 1986. B. Couzinet's Termination of Early Pregnancy by the Progesterone Antagonist RU-486 (Mifepristone) in 1986. Progesterone is indispensable for the maintenance of pregnancy; its elimination results in abortion. The progesterone antagonist RU-486, or mifepristone, which is a 19-nonsteroid, has been used lately for early pregnancy termination. A group of French and American authors conducted a study of 100 women with early unwanted pregnancy during 10 days following the end of expected menstruation. 34 women received 400 mg of RU-486 in the course of 4 days, 26 got 600 mg also in the course 4 days, and 40 women received 800 mg within 2 days. Uterine bleeding appeared in all women in the course of 4 days from the moment of giving the drug, and it lasted 5-17 days. A clear reduction of gonadotropin concentration was observed after 6 days. Ultrasound showed empty uterus within 13 days from the use of the drug. In 15 women after receiving RU-486, the increased level of gonadotropin lasted beyond 6 days, which was indicative of the lack of action of RU-486. In this group of women the uterine cavity was evacuated by nonpharmacological methods. The drug was safe and effective, although 15% of women did not react to it and significant prolonged bleeding occurred in 18% of them.
 ...
PMID:[Progress in endocrinology]. 298 Sep 95

Pergolide (LY127809, CAS 66104-23-2), a dopamine agonist for the treatment of Parkinson's disease, was evaluated for toxicity in acute, subchronic, and chronic studies. Acute toxicity tests using oral, intravenous and intraperitoneal routes were conducted in rats, mice, rabbits, and dogs. The acute oral median lethal doses (MLD) ranged from 8.4 to 33.6 mg/kg in Wistar and Fischer 344 rats, and from 54.0 to 87.2 mg/kg in ICR mice. Oral doses of 20 and 25 mg/kg produced no mortality in rabbits or dogs, respectively. The MLD by the iv route ranged from 0.59 to 0.87 mg/kg for Fischer 344 rats and from 11.6 to 37.1 mg/kg for ICR mice. The predominant signs of toxicity in the acute studies included hyperactivity, poor grooming, ptosis, aggressive behavior, increased gnawing activity, tremors, convulsions, and emesis. In the subchronic and chronic studies, Fischer 344 rats, B6C3F1 mice, and beagle dogs were administered pergolide either by gavage or in the diet for up to 1 year. Daily doses in these studies ranged up to 20 mg/kg for rats, 45 mg/kg for mice, and 5 mg/kg for dogs. The predominant treatment-related effects seen in these studies were attributable to the pharmacologic activity of pergolide. These consisted primarily of CNS-mediated clinical signs in rats and dogs, weight loss or decreased weight gain, emesis in dogs, and inhibition of lysis of corpora lutea with a corresponding increase in the weight of the uterus and ovaries. Pergolide treatment was not associated with any specific target organ toxicity.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:Preclinical toxicology studies with the new dopamine agonist pergolide. Acute, subchronic, and chronic evaluations. 819 91

The human endometrium is a dynamic tissue that undergoes cycles of growth and regression with each menstrual cycle. Adult progenitor stem cells are likely responsible for this remarkable regenerative capacity; these same progenitor stem cells may also have an enhanced capacity to generate endometriosis if shed in a retrograde fashion. The progenitor stem cells reside in the uterus; however, less-committed mesenchymal stem cells may also travel from other tissues such as bone marrow to repopulate the progenitor population. Mesenchymal stem cells are also involved in the pathogenesis of endometriosis and may be the principle source of endometriosis outside of the peritoneal cavity when they differentiate into endometriosis in ectopic locations. Finally, besides progenitor stem cells, recent publications have identified multipotent stem cells in the endometrium. These multipotent stem cells are a readily available source of cells that are useful in tissue engineering and regenerative medicine. Endometrial stem cells have been used to generate chondrocytes, myocytes, neurons, and adiposites in vitro as well as to replace dopaminergic neurons in a murine model of Parkinson's disease.
 ...
PMID:Stem cells in endometrium and their role in the pathogenesis of endometriosis. 2140 24

Recent findings in stem cell biology have presented new perspectives and opportunities for the treatment of reproductive disease. In a departure from the long held dogma of embryologically fixed numbers of oocytes, current literature suggests that human ovaries contain stem cells which form new oocytes even in adulthood and that these stem cells can be cultured in vitro to develop into mature oocytes. These findings have provided new hope and broader options for fertility preservation. Evidence of endometrial regeneration by bone marrow stem cells in endometrial tissue of women who received bone marrow transplant highlight potential for the novel treatments of uterine disorders and supports new theories for the etiology of endometriosis - ectopic transdifferentiation of stem cells. Further, endometrial derived stem cells have been demonstrated to be useful in the treatment of several chronic and often debilitating diseases, including Parkinson's Disease and Diabetes. Other cells that may present future therapeutic benefits for a myriad of disease states include placental and fetal cells which enter maternal circulation during pregnancy and can later promote parenchymal regeneration in maternal tissue. These findings highlight novel functions of the uterus and ovaries. They demonstrate that the uterus is a dynamic organ permeable to fetal stem cells capable of transdifferentiation as well as a renewable source of multipotent stem cells. While we still have much to understand about stem cells, their potential applications in reproductive biology and medicine are countless.
...
PMID:Stem cells and the reproductive system: historical perspective and future directions. 2414 60